Aprea Therapeutics Inc
NASDAQ:APRE
Income Statement
Earnings Waterfall
Aprea Therapeutics Inc
Revenue
|
583.2k
USD
|
Operating Expenses
|
-16.1m
USD
|
Operating Income
|
-15.5m
USD
|
Other Expenses
|
1.2m
USD
|
Net Income
|
-14.3m
USD
|
Income Statement
Aprea Therapeutics Inc
Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
+128%
|
1
+2%
|
|
Operating Income | ||||||||||||||||||||
Operating Expenses |
(18)
|
(22)
|
(30)
|
(37)
|
(46)
|
(51)
|
(53)
|
(51)
|
(47)
|
(44)
|
(37)
|
(35)
|
(124)
|
(119)
|
(113)
|
(110)
|
(15)
|
(15)
|
(16)
|
|
Selling, General & Administrative |
(3)
|
(5)
|
(9)
|
(11)
|
(13)
|
(14)
|
(15)
|
(16)
|
(15)
|
(15)
|
(14)
|
(14)
|
(26)
|
(26)
|
(21)
|
(24)
|
(10)
|
(9)
|
(8)
|
|
Research & Development |
(15)
|
(17)
|
(21)
|
(26)
|
(33)
|
(37)
|
(38)
|
(36)
|
(32)
|
(29)
|
(24)
|
(21)
|
(97)
|
(93)
|
(92)
|
(86)
|
(5)
|
(6)
|
(8)
|
|
Operating Income |
(18)
N/A
|
(22)
-24%
|
(30)
-31%
|
(37)
-25%
|
(46)
-23%
|
(51)
-11%
|
(53)
-4%
|
(51)
+3%
|
(47)
+9%
|
(44)
+6%
|
(37)
+15%
|
(35)
+6%
|
(124)
-250%
|
(119)
+4%
|
(113)
+4%
|
(110)
+3%
|
(15)
+86%
|
(14)
+4%
|
(15)
-7%
|
|
Pre-Tax Income | ||||||||||||||||||||
Interest Income Expense |
2
|
3
|
1
|
3
|
0
|
(1)
|
(1)
|
(3)
|
(1)
|
(1)
|
0
|
(0)
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
|
Pre-Tax Income |
(17)
N/A
|
(20)
-19%
|
(28)
-43%
|
(34)
-21%
|
(45)
-33%
|
(51)
-13%
|
(53)
-5%
|
(54)
-1%
|
(48)
+11%
|
(45)
+6%
|
(37)
+17%
|
(35)
+5%
|
(123)
-249%
|
(118)
+4%
|
(113)
+5%
|
(109)
+3%
|
(14)
+87%
|
(13)
+6%
|
(14)
-8%
|
|
Net Income | ||||||||||||||||||||
Income from Continuing Operations |
(17)
|
(20)
|
(28)
|
(34)
|
(45)
|
(51)
|
(53)
|
(54)
|
(48)
|
(45)
|
(37)
|
(35)
|
(123)
|
(118)
|
(113)
|
(109)
|
(14)
|
(13)
|
(14)
|
|
Net Income (Common) |
(17)
N/A
|
(20)
-19%
|
(28)
-43%
|
(34)
-21%
|
(45)
-33%
|
(51)
-13%
|
(53)
-5%
|
(54)
-1%
|
(48)
+11%
|
(45)
+6%
|
(37)
+17%
|
(35)
+5%
|
(123)
-249%
|
(118)
+4%
|
(113)
+5%
|
(109)
+3%
|
(14)
+87%
|
(13)
+6%
|
(14)
-8%
|
|
EPS (Diluted) |
-17.24
N/A
|
-20.48
-19%
|
-26.72
-30%
|
-32.36
-21%
|
-42.53
-31%
|
-48.26
-13%
|
-50.45
-5%
|
-50.7
0%
|
-44.93
+11%
|
-42.24
+6%
|
-35.02
+17%
|
-32.18
+8%
|
-109.21
-239%
|
-68.19
+38%
|
-67.86
+0%
|
-33.46
+51%
|
-3.78
+89%
|
-3.55
+6%
|
-3.95
-11%
|